https://scholars.lib.ntu.edu.tw/handle/123456789/502821
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.author | Tseng J.-S. | en_US |
dc.contributor.author | Yang T.-Y. | en_US |
dc.contributor.author | Wu C.-Y. | en_US |
dc.contributor.author | Ku W.-H. | en_US |
dc.contributor.author | Chen K.-C. | en_US |
dc.contributor.author | Hsu K.-H. | en_US |
dc.contributor.author | Huang Y.-H. | en_US |
dc.contributor.author | KANG-YI SU | en_US |
dc.contributor.author | SUNG-LIANG YU | en_US |
dc.contributor.author | Chang G.-C. | en_US |
dc.creator | Tseng J.-S.;Yang T.-Y.;Wu C.-Y.;Ku W.-H.;Chen K.-C.;Hsu K.-H.;Huang Y.-H.;Su K.-Y.;Sung-Liang Yu;Chang G.-C. | - |
dc.date.accessioned | 2020-06-17T03:01:30Z | - |
dc.date.available | 2020-06-17T03:01:30Z | - |
dc.date.issued | 2018 | - |
dc.identifier.issn | 1524-9557 | - |
dc.identifier.uri | https://scholars.lib.ntu.edu.tw/handle/123456789/502821 | - |
dc.description.abstract | Immunotherapy targeting the programmed cell death-1 (PD-1) and programmed cell death-ligand 1 (PD-L1) pathway has emerged as an effective treatment for lung cancer patients. It is important to evaluate the practicality of PD-L1 testing in real-world practice. A total of 211 nonsmall cell lung cancer patients were enrolled to detect 5 driver mutations and PD-L1 status (22C3 and SP263 assays) and to evaluate the characteristics of PD-L1 expression and its predictive value of immunotherapy. The PD-L1 positive (?1%) and strong positive (?50%) rate by SP263 assay was 27.0% and 12.8%. The concordance rates between 2 PD-L1 assays while using 1%, 10%, 25%, and 50% positive tumor cells as the cutoffs were 76.8%, 81.5%, 90.5%, and 94.3%, respectively. Smokers and patients without known actionable driver mutation were more likely to present strong positive PD-L1 [adjusted hazard ratio, 5.00 (95% confidence intervalCI, 1.60- 15.64); P=0.006 and 3.59 (95% CI, 1.25-10.33); P=0.018, respectively]. Higher levels of smoking were associated with higher PD-L1 expressions. None of the EGFR, ALK, HER2, or BRAFV600E-mutant nonsmokers displayed strong positive PD-L1 expression by SP263 assay. Among patients undergoing PD-1 checkpoint inhibitors therapy, high PD-L1 expression by SP263 was associated with a longer progression- free survival [adjusted hazard ratio, 0.15 (95% CI, 0.03-0.71); P=0.017]. In conclusion, our results suggest that PD-L1 status remains an important predictor of immunotherapy efficacy. The concordance between 22C3 and SP263 assays was greater at a higher cutoff level of positivity. Patients without known actionable driver mutation, along with smokers, particularly those having high smoking pack-years, were more likely to have strong PD-L1 expression. Copyright ? 2018 Wolters Kluwer Health, Inc. All rights reserved. | - |
dc.relation.ispartof | Journal of Immunotherapy | - |
dc.subject.classification | [SDGs]SDG3 | - |
dc.subject.other | anaplastic lymphoma kinase; B Raf kinase; epidermal growth factor receptor; epidermal growth factor receptor 2; K ras protein; nivolumab; pembrolizumab; programmed death 1 ligand 1; pharmacological biomarker; programmed death 1 ligand 1; adult; aged; Article; cancer immunotherapy; cancer patient; cancer survival; controlled study; female; gene expression; gene mutation; human; major clinical study; male; non small cell lung cancer; overall survival; patient selection; pleura effusion; predictive value; priority journal; progression free survival; retrospective study; smoking; tracheobronchial toilet; genetics; immunotherapy; lung tumor; metabolism; middle aged; mortality; mutation; non small cell lung cancer; procedures; prognosis; very elderly; Adult; Aged; Aged, 80 and over; B7-H1 Antigen; Biomarkers, Pharmacological; Carcinoma, Non-Small-Cell Lung; Female; Humans; Immunotherapy; Lung Neoplasms; Male; Middle Aged; Mutation; Prognosis; Progression-Free Survival | - |
dc.title | Characteristics and Predictive Value of PD-L1 Status in Real-World NonSmall Cell Lung Cancer Patients | en_US |
dc.type | journal article | en |
dc.identifier.doi | 10.1097/CJI.0000000000000226 | - |
dc.identifier.pmid | 29683890 | - |
dc.identifier.scopus | 2-s2.0-85048738706 | - |
dc.relation.pages | 292-299 | - |
dc.relation.journalvolume | 41 | - |
dc.relation.journalissue | 6 | - |
item.openairecristype | http://purl.org/coar/resource_type/c_6501 | - |
item.openairetype | journal article | - |
item.grantfulltext | none | - |
item.cerifentitytype | Publications | - |
item.fulltext | no fulltext | - |
crisitem.author.dept | Clinical Laboratory Sciences and Medical Biotechnology | - |
crisitem.author.dept | Laboratory Medicine-NTUH | - |
crisitem.author.dept | Clinical Laboratory Sciences and Medical Biotechnology | - |
crisitem.author.dept | Pathology | - |
crisitem.author.dept | Medical Device and Imaging | - |
crisitem.author.orcid | 0000-0002-6538-9526 | - |
crisitem.author.orcid | 0000-0003-4535-9036 | - |
crisitem.author.parentorg | College of Medicine | - |
crisitem.author.parentorg | National Taiwan University Hospital | - |
crisitem.author.parentorg | College of Medicine | - |
crisitem.author.parentorg | College of Medicine | - |
crisitem.author.parentorg | College of Medicine | - |
顯示於: | 醫學檢驗暨生物技術學系 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。